A Demjaha1, J M Lappin2, D Stahl3, M X Patel1, J H MacCabe1, O D Howes1, M Heslin4, U A Reininghaus1, K Donoghue5, B Lomas1, M Charalambides1, A Onyejiaka1, P Fearon6, P Jones7, G Doody8, C Morgan1, P Dazzan1, R M Murray1. 1. Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK. 2. School of Psychiatry, University of New South Wales, Sydney, NSW,Australia. 3. Department of Biostatistics,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK. 4. Health Service and Population Research Department,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK. 5. Addictions Department,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK. 6. Department of Psychiatry,Trinity College,Dublin, Republic ofIreland. 7. Department of Psychiatry,University of Cambridge,Cambridge,UK. 8. Division of Psychiatry,University of Nottingham,Nottingham,UK.
Abstract
BACKGROUND: We examined longitudinally the course and predictors of treatment resistance in a large cohort of first-episode psychosis (FEP) patients from initiation of antipsychotic treatment. We hypothesized that antipsychotic treatment resistance is: (a) present at illness onset; and (b) differentially associated with clinical and demographic factors. METHOD: The study sample comprised 323 FEP patients who were studied at first contact and at 10-year follow-up. We collated clinical information on severity of symptoms, antipsychotic medication and treatment adherence during the follow-up period to determine the presence, course and predictors of treatment resistance. RESULTS: From the 23% of the patients, who were treatment resistant, 84% were treatment resistant from illness onset. Multivariable regression analysis revealed that diagnosis of schizophrenia, negative symptoms, younger age at onset, and longer duration of untreated psychosis predicted treatment resistance from illness onset. CONCLUSIONS: The striking majority of treatment-resistant patients do not respond to first-line antipsychotic treatment even at time of FEP. Clinicians must be alert to this subgroup of patients and consider clozapine treatment as early as possible during the first presentation of psychosis.
BACKGROUND: We examined longitudinally the course and predictors of treatment resistance in a large cohort of first-episode psychosis (FEP) patients from initiation of antipsychotic treatment. We hypothesized that antipsychotic treatment resistance is: (a) present at illness onset; and (b) differentially associated with clinical and demographic factors. METHOD: The study sample comprised 323 FEP patients who were studied at first contact and at 10-year follow-up. We collated clinical information on severity of symptoms, antipsychotic medication and treatment adherence during the follow-up period to determine the presence, course and predictors of treatment resistance. RESULTS: From the 23% of the patients, who were treatment resistant, 84% were treatment resistant from illness onset. Multivariable regression analysis revealed that diagnosis of schizophrenia, negative symptoms, younger age at onset, and longer duration of untreated psychosis predicted treatment resistance from illness onset. CONCLUSIONS: The striking majority of treatment-resistant patients do not respond to first-line antipsychotic treatment even at time of FEP. Clinicians must be alert to this subgroup of patients and consider clozapine treatment as early as possible during the first presentation of psychosis.
Authors: Dusan Hirjak; Peter Gass; Michael Deuschle; F Markus Leweke; Andreas Böhringer; Nadine Schenkel; Doris Borgwedel; Marco Heser; Antje Breisacher; Andreas Meyer-Lindenberg Journal: Nervenarzt Date: 2020-03 Impact factor: 1.214
Authors: Linus Jönsson; Jacob Simonsen; Cecilia Brain; Steven Kymes; Louise Watson Journal: Int J Methods Psychiatr Res Date: 2019-04-07 Impact factor: 4.035
Authors: Sherry Kit Wa Chan; Hei Yan Veronica Chan; William G Honer; Tarun Bastiampillai; Yi Nam Suen; Wai Song Yeung; Ming Lam; Wing King Lee; Roger Man King Ng; Christy Lai Ming Hui; Wing Chung Chang; Edwin Ho Ming Lee; Eric Yu Hai Chen Journal: Schizophr Bull Date: 2021-03-16 Impact factor: 9.306
Authors: Vívian T da Silveira; Jivago Röpke; Ana L Matosinhos; Ana C Issy; Elaine A Del Bel; Antônio C de Oliveira; Fabrício A Moreira Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2018-04-24 Impact factor: 3.000
Authors: Ronald Kim; Kati L Healey; Marian T Sepulveda-Orengo; Kathryn J Reissner Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-10-06 Impact factor: 5.067